Your browser doesn't support javascript.
loading
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Gürler, Fatih; Güven, Deniz Can; Aydemir, Ergin; Sütçüoglu, Osman; Inci, Bediz Kurt; Arik, Zafer; Yalçin, Suayib; Özdemir, Nuriye; Özet, Ahmet; Yazici, Ozan.
Afiliación
  • Gürler F; Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
  • Güven DC; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Aydemir E; Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Sütçüoglu O; Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Inci BK; Department of Medical Oncology, Aksaray Training and Research Hospital, Aksaray, Turkey.
  • Arik Z; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Yalçin S; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Özdemir N; Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Özet A; Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Yazici O; Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Turk J Med Sci ; 52(5): 1559-1568, 2022 Oct.
Article en En | MEDLINE | ID: mdl-36422493
ABSTRACT

BACKGROUND:

The aim of our study was to compare the efficacy and the safety of the FLOT and the modified DCF (mDCF) regimens in patients with metastatic gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment.

METHODS:

The medical records of 72 patients were retrospectively reviewed. Survivals and hematological adverse events of the patients were examined. Factors affecting survivals were analyzed in univariate analysis. A multivariate analysis was performed with the factors contributing to survivals in univariate analysis.

RESULTS:

The median PFS (mPFS) was 10.1 months (95% CI, 6.8-13.4) in the FLOT arm (n = 33) and 7.4 months (95% CI, 9.1-21.6) in the mDCF arm (n = 39) (p = 0.041). The median OS (mOS) was 12.9 months (95% CI, 9.7-16.1) in the FLOT arm and 15.4 months (95% CI, 9.1-21.6) in the mDCF arm (p = 0.622). It was found that all grade neutropenia was 51.3% vs. 72.7% (p = 0.063), febrile neutropenia was 8.3% vs. 6.3% (p = 0.743), and thrombocytopenia was 48.7% vs. 51.5% (p = 0.813) in the FLOT and mDCF arms, respectively. Anemia was 59% in the FLOT arm and 100% in the mDCF arm (p < 0.001). Grade 3-4 anemia was 7.7% in the FLOT arm and 24.2% in the mDCF arm (p = 0.052).

DISCUSSION:

It was shown that the mPFS was significantly increased in the FLOT arm compared to the mDCF arm as the first-line treatment in patients with metastatic GC and GEJC. Hematological adverse events were more favorable in the FLOT arm than in the mDCF arm.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Turk J Med Sci Año: 2022 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Turk J Med Sci Año: 2022 Tipo del documento: Article País de afiliación: Turquía